BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28426528)

  • 1. Comparative Analysis of Multicolor Flow Cytometry and Immunohistochemistry for the Detection of Disseminated Tumor Cells.
    Szánthó E; Kárai B; Ivády G; Bedekovics J; Szegedi I; Petrás M; Ujj G; Ujfalusi A; Kiss C; Kappelmayer J; Hevessy Z
    Appl Immunohistochem Mol Morphol; 2018; 26(5):305-315. PubMed ID: 28426528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
    Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
    Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
    Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
    Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
    Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
    Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.
    Ouyang J; Goswami M; Tang G; Peng J; Ravandi F; Daver N; Routbort M; Konoplev S; Lin P; Medeiros LJ; Jorgensen JL; Wang SA
    Am J Hematol; 2015 Jun; 90(6):504-10. PubMed ID: 25732229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
    Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
    Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
    Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
    Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of morphological/immunohistochemical versus nuclear medicine imaging modalities in detecting metastatic bone and/or marrow deposits in neuroblastoma patients.
    Zaher Ael-S; Zaher AM; Moneer MM; El Gamal BM
    J Egypt Natl Canc Inst; 2011 Jun; 23(2):79-88. PubMed ID: 22099965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Analysis of Flow Cytometry and Cytomorphology for Neuroblastoma Cell Detection in Effusion and Bone Marrow Specimens.
    Ye W; Wang J; Li W; Shen H
    Fetal Pediatr Pathol; 2019 Feb; 38(1):1-7. PubMed ID: 30667298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
    Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
    Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometry as a diagnostic tool in neuroblastoma.
    Furlanetto G; Spagnol F; Alegretti AP; Farias MG; Soares VJ; Daudt LE; Loss JF; Scroferneker ML; Michalowski MB
    J Immunol Methods; 2021 Nov; 498():113135. PubMed ID: 34478717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
    Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
    Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples.
    Faulkner LB; Tintori V; Tamburini A; Paoli A; Garaventa A; Viscardi E; Tucci F; Lippi AA; De Bernardi B; Bernini G
    J Hematother; 1998 Aug; 7(4):361-6. PubMed ID: 9735867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine.
    Behdad A; Ross CW; Jacques J; Kota U; Keren D; Stoolman L
    Am J Clin Pathol; 2014 Sep; 142(3):398-410. PubMed ID: 25125632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined cell sorting and FISH for detection of minimal residual disease in bone marrow of children with acute leukemia or solid tumors.
    Sainati L; Spinelli M; Leszl A; Cocito MG; Stella M; Basso G
    Eur J Histochem; 1997; 41 Suppl 2():167-8. PubMed ID: 9859833
    [No Abstract]   [Full Text] [Related]  

  • 20. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.